Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard

Blood (2019) 134 (Supplement_1): 269.

https://doi.org/10.1182/blood-2019-129431

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Chan Y Cheah, MBBS, FRACP, FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Kacey O'Rourke, MBBS FRACP FRCPA, Glen Kennedy, MBBS FRACP FRCPA, Anupkumar George, MBBS FRACP FRCPA, Pasquale Fedele, MBBS, Shuh Ying Tan, MBBS, Stephen Opat, MBBS(Hons) FRACP FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S. Tam, MBBS, FRACP, FRCPA, MD, John F Seymour, MBBS, PhD, FRACP

Blood (2013) 122 (21): 4353.

https://doi.org/10.1182/blood.V122.21.4353.4353

Published: 2013

Journal Articles

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Angela Smiley, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Andrew W. Roberts, MBBS, PhD, Kenneth F Bradstock, MBBS, PhD, FRACP, FRCPA, Richard De Abreu Lourenco, Andrew Spencer, MD

Blood (2013) 122 (21): 537.

https://doi.org/10.1182/blood.V122.21.537.537

Published: 2013

Journal Articles

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Bertrand Coiffier, MD, Barbara Pro, MD, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Francine M. Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dolores Caballero, MD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, Swaminathan Padmanabhan, MBBS, MD, Andrei R. Shustov, MD, Jean Nichols, PhD, Susan Carroll, John Balser, PhD, Steven M. Horwitz, MD

Blood (2011) 118 (21): 591.

https://doi.org/10.1182/blood.V118.21.591.591

Published: 2011

Journal Articles

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Amit S Khot, MBBS, MD, MRCP (UK), FRCPath, Tsin Tsin, Andy Hsu, PhD, Karen Chen, Maureen Loudovaris, Paul Neeson, PhD, Dominic Wall, PhD, Rebecca Sedunary, H. Miles Prince, MBBS, FRACP, FRCPA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD

Blood (2011) 118 (21): 1862.

https://doi.org/10.1182/blood.V118.21.1862.1862

Published: 2011

Journal Articles

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Hang Quach, MBBS, FRACP, FRCPA, MD, Liam Fernyhough, BMBS, BMediSci, FRACP, FRCPA, Ross Henderson, Gillian Corbett, Kevin Lynch, MBBS, David Ritchie, MBBS, FRACP, FRCPA, PhD, Simon J. Harrison, MD, PhD, H. Miles Prince, MBBS, FRACP, FRCPA, MD

Blood (2010) 116 (21): 1961.

https://doi.org/10.1182/blood.V116.21.1961.1961

Published: 2010

Journal Articles

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Peter Gambell, BSc, MHSM, Neil Came, MBBS, FRACP, FRCPA, Kevin Lynch, MB, BS, FFPM, John F. Seymour, MBBS, PhD, FRACP, Miles Prince, MBBS, MD, MRACMA, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA

Blood (2009) 114 (22): 2767.

https://doi.org/10.1182/blood.V114.22.2767.2767

Published: 2009

Journal Articles

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

Michael J. Dickinson, MBBS, Rosemary Hoyt, BN, Andrew Roberts, MBBS PhD, Andrew Grigg, MBBS, John Francis Seymour, MBBS PhD, Jeff Szer, MBBS BSc BMedSci, H. Miles Prince, MBBS(Hons)MD, David Ritchie, MBChB PhD

Blood (2007) 110 (11): 5115.

https://doi.org/10.1182/blood.V110.11.5115.5115

Published: 2007

Journal Articles

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

Miles Prince, MBBS, Hang Quach, MBBS, Paul Neeson, MBBS, Mitch Keegan, Michael Copeman, MBBS, Stefan Peinert, MBBS, Mark Bishton, MBBS, Max Wolf, MBBS, David Ritchie, MBBS, John F. Seymour, MBBS, Dennis Carney, MBBS, David Westerman, MBBS, Simon Harrison, MBBS

Blood (2007) 110 (11): 1167.

https://doi.org/10.1182/blood.V110.11.1167.1167

Published: 2007

Journal Articles

First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).

Andrew Spencer, MBBS, Miles Prince, MBBS, Andrew W. Roberts, MBBS, Kenneth F. Bradstock, MBBS, Ian W. Prosser, MBBS

Blood (2006) 108 (11): 58.

https://doi.org/10.1182/blood.V108.11.58.58

Published: 2006

Journal Articles

LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

Miles Prince, MBBS, D.J. George, MD, R. Johnstone, PhD, C. McCormack, MBBS, L. Ellis, PhD, R. Williams-Truax, P. Atadja, PhD, C. Zhao, MD, M. Dugan, MD, K. Culver, MD

Blood (2006) 108 (11): 2715.

https://doi.org/10.1182/blood.V108.11.2715.2715

Published: 2006

Journal Articles

Appropriate Limits for Microbial Contamination after PBSC Processing and the New European Pharmacopoeia Method for Microbiological Control of Cellular Products.

Dominic Wall, PhD, Peter Gambell, BSc, Alexander Yallouridis, BSc, Luiza Mints-Kotowska, BSc, Irene Lazzarini, BSc, Miles Prince, MBBS,MD,FRACP,FRCPA

Blood (2006) 108 (11): 3386.

https://doi.org/10.1182/blood.V108.11.3386.3386

Published: 2006

Journal Articles

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Saar Gill, MBBS, Steven Lane, MBBS, Julie Crawford, MBBS, Peter Mollee, MBBS, Paula Marlton, MBBS, Gavin Cull, MBBS, Miles Prince, MBBS, MD, John Francis Seymour, MBBS, PhD

Blood (2006) 108 (11): 2441.

https://doi.org/10.1182/blood.V108.11.2441.2441

Published: 2006

Journal Articles

Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).

David S. Ritchie, MBBS, PhD, FRACP, FRCPA, John F. Seymour, MBBS, FRACP, Sarah Thompson, RN, Michael McManus, MBBS, MD, MRCP, FRCR, Miles Prince, MBBS, MD, FRACP, FRCPA

Blood (2005) 106 (11): 5499.

https://doi.org/10.1182/blood.V106.11.5499.5499

Published: 2005

Journal Articles

Pegfilgrastim Compared to Granulocyte Colony Stimulating Factor (G-CSF) with Hyper-CVAD Chemotherapy Regimen for Aggressive Lymphoid Malignancy.

Steven W. Lane, MBBS, Julie Crawford, MBBS, Melita Kenealy, MBBS, Gavin Cull, MBBS, John F. Seymour, MBBS, Miles Prince, MBBS, Paula Marlton, MBBS, Devinder Gill, MBBS, Peter N. Mollee, MBBS MMedSc

Blood (2005) 106 (11): 4274.

https://doi.org/10.1182/blood.V106.11.4274.4274

Published: 2005

Journal Articles

In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma.

David S. Ritchie, MBBS, PhD, FRACP, FRCPA, Linda Mileshkin, MBBS, FRACP, Dominic M. Wall, PhD, Jacques Bartholyens, PhD, Mick Thompson, BSc, Rod Hicks, MBBS, MD, FRACP, Miles Prince, MBBS, MD, FRACP, FRCPA

Blood (2005) 106 (11): 3874.

https://doi.org/10.1182/blood.V106.11.3874.3874

Published: 2005

Journal Articles

Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.

Dominic M. Wall, PhD, Mick Thompson, BSc, Linda Mileshkin, MBBS, FRACP, Bruce Loveland, PhD, Judi Coverdale, BSc, Pei-Xiang Xing, PhD, Jacques Bartholeyns, PhD, Rodney Hicksm, MBBS, MD, FRACP, Miles Prince, MBBS, MD, FRACP, FRCPA

Blood (2005) 106 (11): 3469.

https://doi.org/10.1182/blood.V106.11.3469.3469

Published: 2005

Journal Articles

Prolonged Severe Pancytopenia and Myelodysplastic Features Following Alemtuzumab Therapy in Patients with Cutaneous T-Cell Lymphomas.

Simon D. Gibbs, MBBS, David Alan Westerman, MBBS, John Francis Seymour, MBBS, Miles Prince, MBBS, MD

Blood (2004) 104 (11): 2645.

https://doi.org/10.1182/blood.V104.11.2645.2645

Published: 2004

Journal Articles

Relapse Following Chemotherapy in Aggressive Non-Hodgkin’s Lymphoma Occurs Frequently in Original Sites of Disease.

Max Wolf, MBBS FRACP, Susan J. Morgan, MBBS FRACP FRCPA, Andrew Wirth, MBBS FRACP FRANZCR, John Reynolds, PhD, Janey Stone, MSc, Miles Prince, MBBS FRACP FRCPA MD

Blood (2004) 104 (11): 4587.

https://doi.org/10.1182/blood.V104.11.4587.4587

Published: 2004

NARROW

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Improved Relapse Free Survival Is Predicted by a Negative Pre-Transplant FDG-PET Scan Following Salvage Chemotherapy for Relapsed Diffuse Large B Cell Lymphoma (DLBCL) Treated with Autologous Stem Cell Transplantation.

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).

LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

Appropriate Limits for Microbial Contamination after PBSC Processing and the New European Pharmacopoeia Method for Microbiological Control of Cellular Products.

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).

Pegfilgrastim Compared to Granulocyte Colony Stimulating Factor (G-CSF) with Hyper-CVAD Chemotherapy Regimen for Aggressive Lymphoid Malignancy.

In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma.

Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.

Prolonged Severe Pancytopenia and Myelodysplastic Features Following Alemtuzumab Therapy in Patients with Cutaneous T-Cell Lymphomas.

Relapse Following Chemotherapy in Aggressive Non-Hodgkin’s Lymphoma Occurs Frequently in Original Sites of Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only